Expert Ratings for Bicycle Therapeutics
Within the last quarter, Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings:
SVB Leerink Maintains Outperform on Bicycle Therapeutics, Raises Price Target to $50
SVB Leerink analyst Jonathan Chang maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Outperform and raises the price target from $48 to $50.
HC Wainwright & Co. Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $57
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and lowers the price target from $65 to $57.
Bicycle Therapeutics Announces Publication Of Article In Bioconjugate Chemistry, Describing An Extension Of Its Proprietary Technology Platform Based On Bicyclic Peptides
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that an
Where Bicycle Therapeutics Stands With Analysts
Within the last quarter, Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings:
Where Bicycle Therapeutics Stands With Analysts
Over the past 3 months, 5 analysts have published their opinion on Bicycle Therapeutics (NASDAQ:BCYC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Bicycle Therapeutics To Present Trials In Progress Poster Featuring BT7480 Phase I/II Clinical Trial At The 2022 ASCO Annual Meeting
Bicycle Therapeutics to Present Trials in Progress Poster Featuring BT7480 Phase I/II Clinical Trial at the 2022 ASCO Annual Meeting
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and